In addition, unlike the case for IL-15/PD-1 blockade, mice treated with OMCPmutIL-2 in combination with anti–CTLA-4 remained resistant to tumor rechallenge without additional treatment, suggesting long-term immunity (Figure 9E). Here, CTLA4 is linked to neoplasm.